Triple negative breast cancer is a malignant tumor. If the microinvasive lesion is larger than 1 centimeter, the chance of recurrence is about 30% to 40%, and the recurrence rate is generally high. Triple-negative breast cancer is a breast cancer that is negative for estrogen receptor, progesterone receptor, and proto-oncogene Her-2. Postoperative adjuvant chemotherapy is still needed if and when the extent of microinvasion is more than 1 centimeter, and if the grade of the tumor cells reaches grade III. The majority of triple-negative breast cancer cases are completely cured in 60% to 70% of cases. Most of them recur within 2 to 3 years after surgery. For triple-negative breast cancer, systemic chemotherapy is needed after surgery. The aim of the treatment is to reduce the rate of surgical recurrence, which requires regular follow-up observation. Triple-negative breast cancer generally has a high recurrence rate. It is less effective for radiotherapy, chemotherapy, postoperative, and endocrine therapy. If microinvasion of triple-negative breast cancer is detected, medical attention needs to be sought as soon as possible to avoid delays.
Support Us
Discussion
Share your experience, or seek help from fellow patients.
